<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835471</url>
  </required_header>
  <id_info>
    <org_study_id>NVALT10</org_study_id>
    <nct_id>NCT00835471</nct_id>
  </id_info>
  <brief_title>2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)</brief_title>
  <acronym>NVALT10</acronym>
  <official_title>A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-erlotinib Combination in Pretreated Patients With Advanced NSCLC (NVALT10 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dutch Society of Physicians for Pulmonology and Tuberculosis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dutch Society of Physicians for Pulmonology and Tuberculosis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if the combination of erlotinib and chemotherapy
      (docetaxel in case of squamous cell NSCLC or pemetrexed in case of other histological types)
      is superior to erlotinib alone and has acceptable tolerability and safety in the 2nd line
      treatment of patients with advanced/metastatic non-small cell lung cancer (NSCLC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open randomized multicenter phase II study in patiÃ«nts in need of 2nd line treatment for
      advanced/metastatic NSCLC. Efficacy and safety of monotherapy with erlotinib will be compared
      with combination therapy of erlotinib and chemotherapy. In recent studies it was established
      that pemetrexed activity is more pronounced in non-squamous NSCLC in comparison to squamous
      cell carcinoma. Therefore in patients with non-squamous carcinoma pemetrexed will be used. As
      in second line treatment of NSCLC docetaxel is registered also for usage in patients with
      squamous cell carcinoma, docetaxel will be used in patients with squamous histology.

      Chemotherapy will be limited to 4 courses. Erlotinib will be continued until disease
      progression or unacceptable toxicity.

      Erlotinib as monotherapy will be administered continuously. In combination with chemotherapy,
      erlotinib will be given from day 2-16 of every course of 3 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Imaging</measure>
    <time_frame>Every 6 weeks until disease progression</time_frame>
    <description>Chest X ray, CT. Bone scan, brain scan (if clinically indicated) for Progression free survival Response rate Duration of response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Every 3 weeks during chemotherapy</time_frame>
    <description>Haematology, chemistry, adverse events, physical examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib plus docetaxel (squamous cell NSCLC) or pemetrexed (non-squamous cell NSCLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Erlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib plus docetaxel or pemetrexed</intervention_name>
    <description>non-squamous carcinoma: pemetrexed 500 mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16, every 21 days. Pemetrexed will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.
squamous carcinoma: Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days. Docetaxel will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Tarceva</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>erlotinib 150 mg/day continuously until disease progression</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed NSCLC, locally advanced and metastatic
             disease stage IIIB and IV. Evidence of disease progression after one or two cytotoxic
             treatment regimens which should have included a platinum agent.

          2. Complete recovery from prior chemotherapy side effects to &lt; Grade 2.

          3. At least one unidimensional measurable lesion meeting RECIST criteria.

          4. ECOG PS 0-2.

          5. Age &gt; 18 years.

          6. Adequate organ function, including:

               -  Adequate bone marrow reserve: ANC &gt; 1.5 x 109/L, platelets &gt; 100 x 109/L.

               -  Hepatic: bilirubin &lt;1.5 x ULN, AP, ALT, AST &lt; 1.5 x ULN AP, ALT, and AST &lt;5 x ULN
                  is acceptable if the liver has tumor involvement

               -  Renal: calculated creatinin clearance &gt; 40 ml/min based on the Cockcroft-Gault
                  formula.

          7. Estimated life expectancy &gt;12 weeks.

          8. Male and female patients with reproductive potential must use an approved
             contraceptive method, if appropriate. Female patients with childbearing potential must
             have a negative serum pregnancy test within 7 days prior to study enrollment.

          9. Signed informed consent.

         10. Patient compliance and geographical proximity that allow adequate follow up.

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Patients with medical risks because of non-malignant disease as well as those with
             active uncontrolled infection.

          3. Documented brain metastases unless the patient has completed local therapy for central
             nervous system metastases and has been off corticosteroids for at least two weeks
             before enrollment.

          4. Previous treatment with an EGFR-TKI, or in non-squamous histology earlier treatment
             with pemetrexed and in squamous earlier treatment with docetaxel.

          5. Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a
             5-day period (5 day period for long-acting agents such as piroxicam).

          6. Inability or unwillingness to take folic acid, vitamin B-12 supplementation or
             dexamethasone.

          7. Concomitant treatment with any other experimental drug under investigation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim G. Aerts, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Amphia Ziekenhuis, Breda, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henk E. Coderington, MD</last_name>
    <role>Study Director</role>
    <affiliation>HagaZiekenhuis, The Hague, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joachim G. Aerts, MD PhD</last_name>
    <phone>+31 765953121</phone>
    <email>rsc@rsconsultancy.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henk E. Codrington, MD</last_name>
    <phone>+31 702102076</phone>
    <email>rsc@rsconsultancy.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VU medisch centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Smit</last_name>
      <email>ef.smit@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>Egbert F. Smit, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rikers</last_name>
      <email>mscrk@rkz.nl</email>
    </contact>
    <investigator>
      <last_name>C. H. Rikers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aerts</last_name>
      <email>jaerts@amphia.nl</email>
    </contact>
    <investigator>
      <last_name>Joachim G. Aerts, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pannekoek</last_name>
      <email>pkoek@rdgg.nl</email>
    </contact>
    <investigator>
      <last_name>B. J. Pannekoek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biesma</last_name>
      <email>b.biesma@jbz.nl</email>
    </contact>
    <investigator>
      <last_name>Bonne Biesma, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina-Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>van den Borne</last_name>
      <email>ben.vd.borne@cze.nl</email>
    </contact>
    <investigator>
      <last_name>Ben E. van den Borne, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>van Putten</last_name>
      <email>jwg.van.putten@mzh.nl</email>
    </contact>
    <investigator>
      <last_name>John W. van Putten, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weenink</last_name>
      <email>weenink@kg.nl</email>
    </contact>
    <investigator>
      <last_name>C. Weenink, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dingemans</last_name>
      <email>a.c.dingemans@lung.azm.nl</email>
    </contact>
    <investigator>
      <last_name>A. C. Dingemans, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Sint Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>van der Drift</last_name>
      <email>m.vanderdrift@ulc.umcn.nl</email>
    </contact>
    <investigator>
      <last_name>M. A. van der Drift, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Slingerland</last_name>
      <email>slingerlandr@mcrz.nl</email>
    </contact>
    <investigator>
      <last_name>Rob Slingerland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>in 't Veen</last_name>
      <email>h.intveen@sfg.nl</email>
    </contact>
    <investigator>
      <last_name>J. C. in 't Veen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Codrington</last_name>
      <email>h.codrington@hagaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Henk E. Codrington, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stigt</last_name>
      <email>j.a.stigt@isala.nl</email>
    </contact>
    <investigator>
      <last_name>Jos A. Stigt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.nvalt.nl</url>
    <description>Dutch Society of Physicians for Pulmonology and Tuberculosis (NVALT)</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <last_update_submitted>July 23, 2010</last_update_submitted>
  <last_update_submitted_qc>July 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>J.G.J.V. Aerts MD PhD</name_title>
    <organization>Dutch Society of Physicians for Pulmonology and Tuberculosis (NVALT)</organization>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>non-small-cell</keyword>
  <keyword>erlotinib</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

